164 related articles for article (PubMed ID: 38769987)
1. Cytomegalovirus Matching in Deceased Donor Kidney Allocation: Results From a U.S. National Simulation Model.
Sandikçi B; Ulukuş MY; Ergün MA; Tanriöver B
Transplant Direct; 2024 Jun; 10(6):e1622. PubMed ID: 38769987
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis.
Leeaphorn N; Garg N; Thamcharoen N; Khankin EV; Cardarelli F; Pavlakis M
Am J Transplant; 2019 Feb; 19(2):573-584. PubMed ID: 30431703
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus serologic matching in deceased donor kidney allocation optimizes high- and low-risk (D+R- and D-R-) profiles and does not adversely affect transplant rates.
Lockridge J; Roberts D; Olyaei A; Noble BN; Langewisch E; Rehman S; Stack M; Scott D; Orloff S; Shaut C; Gardner B; Bennett W; Norman D
Am J Transplant; 2020 Dec; 20(12):3502-3508. PubMed ID: 32372499
[TBL] [Abstract][Full Text] [Related]
4. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
Johnson RJ; Clatworthy MR; Birch R; Hammad A; Bradley JA
Transplantation; 2009 Jul; 88(1):77-82. PubMed ID: 19584684
[TBL] [Abstract][Full Text] [Related]
5. Impact of Cytomegalovirus Serostatus on Allograft Loss and Mortality Within the First Year After Kidney Transplantation: An Analysis of the National Transplant Registry.
Bruminhent J; Dajsakdipon T; Ingsathit A; Supaporn T; Prommool S; Watcharananan SP
Transplant Proc; 2020 Apr; 52(3):829-835. PubMed ID: 32113693
[TBL] [Abstract][Full Text] [Related]
6. Patient years lost due to cytomegalovirus serostatus mismatching in the scientific registry of transplant recipients.
Abidi MZ; Schold JD; Kaplan B; Weinberg A; Erlandson KM; Malamon JS
Front Immunol; 2023; 14():1292648. PubMed ID: 38264645
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
[TBL] [Abstract][Full Text] [Related]
8. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
Harvala H; Stewart C; Muller K; Burns S; Marson L; MacGilchrist A; Johannessen I
J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
[TBL] [Abstract][Full Text] [Related]
9. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
Mabilangan C; Preiksaitis JK; Cervera C;
Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
[TBL] [Abstract][Full Text] [Related]
10. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
Mabilangan C; Preiksaitis J; Cervera C;
Transpl Infect Dis; 2018 Oct; 20(5):e12964. PubMed ID: 29981174
[TBL] [Abstract][Full Text] [Related]
11. Major Variation across Local Transplant Centers in Probability of Kidney Transplant for Wait-Listed Patients.
King KL; Husain SA; Schold JD; Patzer RE; Reese PP; Jin Z; Ratner LE; Cohen DJ; Pastan SO; Mohan S
J Am Soc Nephrol; 2020 Dec; 31(12):2900-2911. PubMed ID: 33037131
[TBL] [Abstract][Full Text] [Related]
12. Estimating Waiting Time for Deceased Donor Renal Transplantion in the Era of New Kidney Allocation System.
Torlak F; Ayvaci MU; Ahsen ME; Arce C; Vazquez MA; Tanriover B
Transplant Proc; 2016; 48(6):1916-9. PubMed ID: 27569922
[TBL] [Abstract][Full Text] [Related]
13. Association Between Declined Offers of Deceased Donor Kidney Allograft and Outcomes in Kidney Transplant Candidates.
Husain SA; King KL; Pastan S; Patzer RE; Cohen DJ; Radhakrishnan J; Mohan S
JAMA Netw Open; 2019 Aug; 2(8):e1910312. PubMed ID: 31469394
[TBL] [Abstract][Full Text] [Related]
14. The Clinical and Economic Benefit of CMV Matching in Kidney Transplant: A Decision Analysis.
Axelrod DA; Chang SH; Lentine KL; Schnitzler MA; Norman D; Olyaei A; Malinoski D; Dharnidharka V; Segev D; Istre GR; Lockridge JB
Transplantation; 2022 Jun; 106(6):1227-1232. PubMed ID: 34310099
[TBL] [Abstract][Full Text] [Related]
15. Allocating Deceased Donor Kidneys to Candidates with High Panel-Reactive Antibodies.
Gebel HM; Kasiske BL; Gustafson SK; Pyke J; Shteyn E; Israni AK; Bray RA; Snyder JJ; Friedewald JJ; Segev DL
Clin J Am Soc Nephrol; 2016 Mar; 11(3):505-11. PubMed ID: 26839235
[TBL] [Abstract][Full Text] [Related]
16. Donor Graft Cytomegalovirus Serostatus and the Risk of Arterial and Venous Thrombotic Events in Seronegative Recipients After Non-Thoracic Solid Organ Transplantation.
Belga S; MacDonald C; Chiang D; Kabbani D; Shojai S; Abraldes JG; Cervera C
Clin Infect Dis; 2021 Mar; 72(5):845-852. PubMed ID: 32025704
[TBL] [Abstract][Full Text] [Related]
17. Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients.
Vutien P; Perkins J; Biggins SW; Reyes J; Imlay H; Limaye AP
Liver Transpl; 2021 Sep; 27(9):1302-1311. PubMed ID: 33687777
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus & Epstein Barr Virus serostatus as a predictor of the long-term outcome of kidney transplantation.
Le Page AK; Mackie FE; McTaggart SJ; Kennedy SE
Nephrology (Carlton); 2013 Dec; 18(12):813-9. PubMed ID: 23927085
[TBL] [Abstract][Full Text] [Related]
19. The Impact of the New Kidney Allocation System on Prior Living Kidney Donors' Access to Deceased Donor Kidney Transplants: An Early Look.
Wainright JL; Kucheryavaya AY; Klassen DK; Stewart DE
Am J Transplant; 2017 Apr; 17(4):1103-1111. PubMed ID: 27805305
[TBL] [Abstract][Full Text] [Related]
20. Allocation of the Highest Quality Kidneys and Transplant Outcomes Under the New Kidney Allocation System.
Sethi S; Najjar R; Peng A; Mirocha J; Vo A; Bunnapradist S; Jordan SC; Huang E
Am J Kidney Dis; 2019 May; 73(5):605-614. PubMed ID: 30929853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
